Prevention of respiratory infections in children
https://doi.org/10.21518/2079-701X-2014-14-18-21
Abstract
Respiratory infections remain a challenge in pediatrics because of their high prevalence and economic burden both for individuals and society as a whole, as they account for 60 to 90% of all infectious diseases in children among infectious diseases. They are recorded everywhere and all year round, reaching epidemic proportions during the seasonal morbidity rise from October to March. Although the majority of acute respiratory infections (ARI) are mild course and cause no complications, they impair well being of children and hinder their daily activities [3].
About the Author
N. G. Kolosova
the First Moscow State Medical University named after I.M. Sechenov
Russian Federation
Russian Federation
References
1. Афиногенова В.П., Лукачев И.В., Костинов М.П. Иммунотерапия: механизм действия и клиническое применение иммунокорригирующих препаратов. Лечащий врач, 2010, 4.
2. Богомолова И.К., Носков КГ. Эффективность вакцинотерапии рибомунилом у больных бронхиальной астмой. Забайкальский медицинский вестник, 2010, 1: 3-5.
3. Волков И.К., Геппе Н.А., Фролкова Е.В., Шахназарова М.Д. Применение рибосомальной вакцины (Рибомунил) в профилактике респираторных заболеваний у детей. Фарматека, 2014, 3: 66-71.
4. Коровина Н.А., Чебуркин А.В., Заплатников А.Л., Захарова И.Н. Иммунокорригирующая терапия часто и длительно болеющих детей.
5. Опыт применения Рибомунила в российской педиатрической практике. Сборник научных трудов. Под ред. Н.А. Коровиной. М., 2002.
6. Пикуза О.И., Закирова А.М., Хакимова А.Ф. Клинико-иммунологическая эффективность бактериальных лизатов у часто болеющих детей. РМЖ, 2012, 96(2): 45-47.
7. Bellami JA, Olivieri D, Seranno E. Ribosomal immunostimulation: assessment of studies evaluating its clinical relevance in the prevention ol upper and lower respiratory tract infections in children and adults. BioDrugs, 2003, 17: 355-367.
8. Bousquet J, Fiocchi A. Prevention of recurrent respiratory tract infections in children using a ribosomal immunotherapeutic agent: a clinical review. Paediatr. Drugs. 2006, 8(4): 235-43.
9. Boyle P, Bellanto JA, Robertson C. Mela-analysis of published clinical trials of a ribosomal vaccine (Ribomunyl® in prevention of respiratory infections. BioDrugs. 2000, 14: 389-408.
10. Cahot E, Libon C, Kernels S el al. Translocation of ribosomal immuno-stimulant through an in vitro-reconstituted digestive barrier containing M-like cells. Scand.J. Immunol. 2000, 52: 588-94.
11. Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJL Immunostimulants for preventing respiratory tract infection in children. Cochrane Database Systematic Rev. 2006, Issue 4: CD004974.
12. Jongmans W, Tiemessen DM, van Vlodrop IJ et al. Th1-polarizing capacity of clinical-grade dendritic cells triggered by Ribomunyl but is compromised by PGE2.J. Immunother. 2005, 28: 480-87.
13. Zanib C, Bene MC, Perruchet AM et al. Bacterial crude extracts of ribosomes are recognized similary by peripheral and mucosal B cells. PPMS Immunol. Med. Microbiol. 1994, 10: 11-8.
Review
For citations:
Kolosova NG. Prevention of respiratory infections in children. Meditsinskiy sovet = Medical Council. 2014;(14):18-21. (In Russ.) https://doi.org/10.21518/2079-701X-2014-14-18-21
Views:
487
Email this article 